Does the media prefer CYPH or IRD?

In the previous week, Opus Genetics had 9 more articles in the media than Cypherpunk Technologies. MarketBeat recorded 10 mentions for Opus Genetics and 1 mentions for Cypherpunk Technologies. Cypherpunk Technologies' average media sentiment score of 0.67 beat Opus Genetics' score of 0.12 indicating that Cypherpunk Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cypherpunk Technologies 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Opus Genetics 1 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to CYPH or ORGO?

In the previous week, Organogenesis had 12 more articles in the media than Cypherpunk Technologies. MarketBeat recorded 13 mentions for Organogenesis and 1 mentions for Cypherpunk Technologies. Cypherpunk Technologies' average media sentiment score of 0.67 beat Organogenesis' score of -0.14 indicating that Cypherpunk Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cypherpunk Technologies 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Organogenesis 1 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer CYPH or FATE?

In the previous week, Fate Therapeutics had 3 more articles in the media than Cypherpunk Technologies. MarketBeat recorded 4 mentions for Fate Therapeutics and 1 mentions for Cypherpunk Technologies. Cypherpunk Technologies' average media sentiment score of 0.67 beat Fate Therapeutics' score of 0.39 indicating that Cypherpunk Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cypherpunk Technologies 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fate Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer CYPH or MYGN?

In the previous week, Myriad Genetics had 12 more articles in the media than Cypherpunk Technologies. MarketBeat recorded 13 mentions for Myriad Genetics and 1 mentions for Cypherpunk Technologies. Cypherpunk Technologies' average media sentiment score of 0.67 beat Myriad Genetics' score of -0.02 indicating that Cypherpunk Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cypherpunk Technologies 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Myriad Genetics 1 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, CYPH or AVXL?

Cypherpunk Technologies is trading at a lower price-to-earnings ratio than Anavex Life Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cypherpunk Technologies N/A N/A $4.82M -$0.02 N/A Anavex Life Sciences N/A N/A -$46.38M -$0.39 N/A

Is CYPH or AVXL more profitable?

Anavex Life Sciences' return on equity of -32.73% beat Cypherpunk Technologies' return on equity. Company Net Margins Return on Equity Return on Assets Cypherpunk Technologies N/A -48.33% -42.21% Anavex Life Sciences N/A -32.73% -30.15%

Does the media refer more to CYPH or AVXL?

In the previous week, Cypherpunk Technologies and Cypherpunk Technologies both had 1 articles in the media. Cypherpunk Technologies' average media sentiment score of 0.67 beat Anavex Life Sciences' score of 0.13 indicating that Cypherpunk Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cypherpunk Technologies 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Anavex Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Cypherpunk Technologies (CYPH) Competitors

$0.68 -0.01 (-1.21%)

As of 02:40 PM Eastern

Compare

CYPH vs. IRD, ORGO, FATE, MYGN, and AVXL

Should you buy Cypherpunk Technologies stock or one of its competitors? MarketBeat compares Cypherpunk Technologies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cypherpunk Technologies include Opus Genetics (IRD), Organogenesis (ORGO), Fate Therapeutics (FATE), Myriad Genetics (MYGN), and Anavex Life Sciences (AVXL). These companies are all part of the "biotechnology" industry.

How does Cypherpunk Technologies compare to Opus Genetics?

Cypherpunk Technologies (NASDAQ:CYPH) and Opus Genetics (NASDAQ:IRD) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership, media sentiment and risk.

Cypherpunk Technologies has higher earnings, but lower revenue than Opus Genetics. Cypherpunk Technologies is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cypherpunk Technologies	N/A	N/A	$4.82M	-$0.02	N/A
Opus Genetics	$14.20M	21.51	-$49.59M	-$1.35	N/A

30.5% of Cypherpunk Technologies shares are owned by institutional investors. Comparatively, 15.0% of Opus Genetics shares are owned by institutional investors. 3.5% of Cypherpunk Technologies shares are owned by company insiders. Comparatively, 11.7% of Opus Genetics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Opus Genetics had 9 more articles in the media than Cypherpunk Technologies. MarketBeat recorded 10 mentions for Opus Genetics and 1 mentions for Cypherpunk Technologies. Cypherpunk Technologies' average media sentiment score of 0.67 beat Opus Genetics' score of 0.12 indicating that Cypherpunk Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cypherpunk Technologies	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Opus Genetics	1 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Cypherpunk Technologies currently has a consensus target price of $0.90, suggesting a potential upside of 32.29%. Opus Genetics has a consensus target price of $10.69, suggesting a potential upside of 188.98%. Given Opus Genetics' stronger consensus rating and higher probable upside, analysts clearly believe Opus Genetics is more favorable than Cypherpunk Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cypherpunk Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Opus Genetics	2 Sell rating(s)	0 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.83

Cypherpunk Technologies has a net margin of 0.00% compared to Opus Genetics' net margin of -1,091.82%. Cypherpunk Technologies' return on equity of -48.33% beat Opus Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cypherpunk Technologies	N/A	-48.33%	-42.21%
Opus Genetics	-1,091.82%	-338.88%	-150.13%

Cypherpunk Technologies has a beta of 0.09, meaning that its share price is 91% less volatile than the broader market. Comparatively, Opus Genetics has a beta of 0.59, meaning that its share price is 41% less volatile than the broader market.

Summary

Opus Genetics beats Cypherpunk Technologies on 8 of the 15 factors compared between the two stocks.

How does Cypherpunk Technologies compare to Organogenesis?

Cypherpunk Technologies (NASDAQ:CYPH) and Organogenesis (NASDAQ:ORGO) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, media sentiment, dividends, valuation and earnings.

In the previous week, Organogenesis had 12 more articles in the media than Cypherpunk Technologies. MarketBeat recorded 13 mentions for Organogenesis and 1 mentions for Cypherpunk Technologies. Cypherpunk Technologies' average media sentiment score of 0.67 beat Organogenesis' score of -0.14 indicating that Cypherpunk Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cypherpunk Technologies	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Organogenesis	1 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

30.5% of Cypherpunk Technologies shares are owned by institutional investors. Comparatively, 49.6% of Organogenesis shares are owned by institutional investors. 3.5% of Cypherpunk Technologies shares are owned by insiders. Comparatively, 18.8% of Organogenesis shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Organogenesis has higher revenue and earnings than Cypherpunk Technologies. Cypherpunk Technologies is trading at a lower price-to-earnings ratio than Organogenesis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cypherpunk Technologies	N/A	N/A	$4.82M	-$0.02	N/A
Organogenesis	$564.17M	0.43	$37.03M	-$0.86	N/A

Cypherpunk Technologies has a net margin of 0.00% compared to Organogenesis' net margin of -19.94%. Organogenesis' return on equity of -23.89% beat Cypherpunk Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cypherpunk Technologies	N/A	-48.33%	-42.21%
Organogenesis	-19.94%	-23.89%	-11.13%

Cypherpunk Technologies has a beta of 0.09, meaning that its share price is 91% less volatile than the broader market. Comparatively, Organogenesis has a beta of 1.34, meaning that its share price is 34% more volatile than the broader market.

Cypherpunk Technologies presently has a consensus target price of $0.90, indicating a potential upside of 32.29%. Organogenesis has a consensus target price of $4.33, indicating a potential upside of 132.35%. Given Organogenesis' higher probable upside, analysts clearly believe Organogenesis is more favorable than Cypherpunk Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cypherpunk Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Organogenesis	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Summary

Organogenesis beats Cypherpunk Technologies on 10 of the 15 factors compared between the two stocks.

How does Cypherpunk Technologies compare to Fate Therapeutics?

Cypherpunk Technologies (NASDAQ:CYPH) and Fate Therapeutics (NASDAQ:FATE) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, media sentiment, risk, dividends, earnings and institutional ownership.

Cypherpunk Technologies has a net margin of 0.00% compared to Fate Therapeutics' net margin of -2,056.79%. Cypherpunk Technologies' return on equity of -48.33% beat Fate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cypherpunk Technologies	N/A	-48.33%	-42.21%
Fate Therapeutics	-2,056.79%	-58.89%	-39.39%

Cypherpunk Technologies presently has a consensus target price of $0.90, indicating a potential upside of 32.29%. Fate Therapeutics has a consensus target price of $5.13, indicating a potential upside of 86.03%. Given Fate Therapeutics' higher probable upside, analysts clearly believe Fate Therapeutics is more favorable than Cypherpunk Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cypherpunk Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Fate Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

30.5% of Cypherpunk Technologies shares are held by institutional investors. Comparatively, 97.5% of Fate Therapeutics shares are held by institutional investors. 3.5% of Cypherpunk Technologies shares are held by insiders. Comparatively, 4.7% of Fate Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Cypherpunk Technologies has a beta of 0.09, indicating that its share price is 91% less volatile than the broader market. Comparatively, Fate Therapeutics has a beta of 2.52, indicating that its share price is 152% more volatile than the broader market.

Cypherpunk Technologies has higher earnings, but lower revenue than Fate Therapeutics. Cypherpunk Technologies is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cypherpunk Technologies	N/A	N/A	$4.82M	-$0.02	N/A
Fate Therapeutics	$6.65M	48.29	-$136.32M	-$1.09	N/A

In the previous week, Fate Therapeutics had 3 more articles in the media than Cypherpunk Technologies. MarketBeat recorded 4 mentions for Fate Therapeutics and 1 mentions for Cypherpunk Technologies. Cypherpunk Technologies' average media sentiment score of 0.67 beat Fate Therapeutics' score of 0.39 indicating that Cypherpunk Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cypherpunk Technologies	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fate Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Fate Therapeutics beats Cypherpunk Technologies on 9 of the 16 factors compared between the two stocks.

How does Cypherpunk Technologies compare to Myriad Genetics?

Cypherpunk Technologies (NASDAQ:CYPH) and Myriad Genetics (NASDAQ:MYGN) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, media sentiment, institutional ownership, profitability and dividends.

Cypherpunk Technologies has higher earnings, but lower revenue than Myriad Genetics. Cypherpunk Technologies is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cypherpunk Technologies	N/A	N/A	$4.82M	-$0.02	N/A
Myriad Genetics	$806.60M	0.39	-$365.90M	-$1.19	N/A

Cypherpunk Technologies has a beta of 0.09, meaning that its stock price is 91% less volatile than the broader market. Comparatively, Myriad Genetics has a beta of 1.69, meaning that its stock price is 69% more volatile than the broader market.

Cypherpunk Technologies has a net margin of 0.00% compared to Myriad Genetics' net margin of -13.96%. Myriad Genetics' return on equity of -16.09% beat Cypherpunk Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cypherpunk Technologies	N/A	-48.33%	-42.21%
Myriad Genetics	-13.96%	-16.09%	-8.10%

Cypherpunk Technologies presently has a consensus price target of $0.90, suggesting a potential upside of 32.29%. Myriad Genetics has a consensus price target of $5.38, suggesting a potential upside of 64.12%. Given Myriad Genetics' higher possible upside, analysts clearly believe Myriad Genetics is more favorable than Cypherpunk Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cypherpunk Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Myriad Genetics	2 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.83

In the previous week, Myriad Genetics had 12 more articles in the media than Cypherpunk Technologies. MarketBeat recorded 13 mentions for Myriad Genetics and 1 mentions for Cypherpunk Technologies. Cypherpunk Technologies' average media sentiment score of 0.67 beat Myriad Genetics' score of -0.02 indicating that Cypherpunk Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cypherpunk Technologies	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Myriad Genetics	1 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

30.5% of Cypherpunk Technologies shares are held by institutional investors. Comparatively, 99.0% of Myriad Genetics shares are held by institutional investors. 3.5% of Cypherpunk Technologies shares are held by company insiders. Comparatively, 1.9% of Myriad Genetics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Myriad Genetics beats Cypherpunk Technologies on 9 of the 16 factors compared between the two stocks.

How does Cypherpunk Technologies compare to Anavex Life Sciences?

Cypherpunk Technologies (NASDAQ:CYPH) and Anavex Life Sciences (NASDAQ:AVXL) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.

Cypherpunk Technologies has a beta of 0.09, suggesting that its share price is 91% less volatile than the broader market. Comparatively, Anavex Life Sciences has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market.

In the previous week, Cypherpunk Technologies and Cypherpunk Technologies both had 1 articles in the media. Cypherpunk Technologies' average media sentiment score of 0.67 beat Anavex Life Sciences' score of 0.13 indicating that Cypherpunk Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cypherpunk Technologies	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Anavex Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

30.5% of Cypherpunk Technologies shares are owned by institutional investors. Comparatively, 31.6% of Anavex Life Sciences shares are owned by institutional investors. 3.5% of Cypherpunk Technologies shares are owned by insiders. Comparatively, 11.0% of Anavex Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Cypherpunk Technologies presently has a consensus target price of $0.90, suggesting a potential upside of 32.29%. Anavex Life Sciences has a consensus target price of $21.33, suggesting a potential upside of 530.23%. Given Anavex Life Sciences' higher possible upside, analysts plainly believe Anavex Life Sciences is more favorable than Cypherpunk Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cypherpunk Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Cypherpunk Technologies is trading at a lower price-to-earnings ratio than Anavex Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cypherpunk Technologies	N/A	N/A	$4.82M	-$0.02	N/A
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.39	N/A

Anavex Life Sciences' return on equity of -32.73% beat Cypherpunk Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cypherpunk Technologies	N/A	-48.33%	-42.21%
Anavex Life Sciences	N/A	-32.73%	-30.15%

Summary

Anavex Life Sciences beats Cypherpunk Technologies on 8 of the 13 factors compared between the two stocks.

Get Cypherpunk Technologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CYPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CYPH vs. The Competition

Export

Metric	Cypherpunk Technologies	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$72.43M	$3.71B	$7.04B	$12.92B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-34.00	9.08	269.95	24.78
Price / Sales	N/A	1,267.38	650.49	107.95
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	0.37	17.64	11.25	6.43
Net Income	$4.82M	-$13.25M	$3.45B	$347.27M
7 Day Performance	6.83%	5.21%	3.49%	2.53%
1 Month Performance	-3.22%	-1.94%	-0.66%	-1.03%
1 Year Performance	115.56%	60.76%	77.20%	23.28%

Cypherpunk Technologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CYPH Cypherpunk Technologies	2.4651 of 5 stars	$0.68 -1.2%	$0.90 +32.3%	+118.2%	$72.43M	N/A	N/A	40	Gap Up
IRD Opus Genetics	2.6977 of 5 stars	$3.72 -1.6%	$10.77 +189.5%	+242.1%	$312.10M	$14.20M	N/A	14	Earnings Report Analyst Forecast
ORGO Organogenesis	1.6367 of 5 stars	$2.41 +1.7%	$5.75 +138.6%	-59.1%	$304.96M	$564.17M	N/A	950	Earnings Report Analyst Forecast
FATE Fate Therapeutics	3.3235 of 5 stars	$2.49 -4.2%	$5.13 +105.8%	+203.9%	$303.05M	$6.65M	N/A	550	News Coverage Upcoming Earnings
MYGN Myriad Genetics	3.429 of 5 stars	$3.18 +1.0%	$5.38 +69.0%	-48.4%	$301.30M	$806.60M	N/A	2,700	Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CYPH) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cypherpunk Technologies (CYPH) Competitors

CYPH vs. IRD, ORGO, FATE, MYGN, and AVXL

How does Cypherpunk Technologies compare to Opus Genetics?

Summary

How does Cypherpunk Technologies compare to Organogenesis?

Summary

How does Cypherpunk Technologies compare to Fate Therapeutics?

Summary

How does Cypherpunk Technologies compare to Myriad Genetics?

Summary

How does Cypherpunk Technologies compare to Anavex Life Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYPH vs. The Competition

Cypherpunk Technologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cypherpunk Technologies (CYPH) Competitors

CYPH vs. IRD, ORGO, FATE, MYGN, and AVXL

How does Cypherpunk Technologies compare to Opus Genetics?

Which has stronger earnings and valuation, CYPH or IRD?

Do insiders & institutionals hold more shares of CYPH or IRD?

Does the media prefer CYPH or IRD?

Do analysts prefer CYPH or IRD?

Is CYPH or IRD more profitable?

Which has more volatility & risk, CYPH or IRD?

Summary

How does Cypherpunk Technologies compare to Organogenesis?

Does the media refer more to CYPH or ORGO?

Do institutionals and insiders believe in CYPH or ORGO?

Which has higher earnings and valuation, CYPH or ORGO?

Is CYPH or ORGO more profitable?

Which has more volatility and risk, CYPH or ORGO?

Do analysts prefer CYPH or ORGO?

Summary

How does Cypherpunk Technologies compare to Fate Therapeutics?

Is CYPH or FATE more profitable?

Do analysts rate CYPH or FATE?

Do institutionals & insiders hold more shares of CYPH or FATE?

Which has more volatility & risk, CYPH or FATE?

Which has stronger earnings & valuation, CYPH or FATE?

Does the media prefer CYPH or FATE?

Summary

How does Cypherpunk Technologies compare to Myriad Genetics?

Which has higher earnings & valuation, CYPH or MYGN?

Which has more risk and volatility, CYPH or MYGN?

Is CYPH or MYGN more profitable?

Do analysts recommend CYPH or MYGN?

Does the media prefer CYPH or MYGN?

Do insiders & institutionals believe in CYPH or MYGN?

Summary

How does Cypherpunk Technologies compare to Anavex Life Sciences?

Which has more volatility and risk, CYPH or AVXL?

Does the media refer more to CYPH or AVXL?

Do institutionals and insiders hold more shares of CYPH or AVXL?

Do analysts recommend CYPH or AVXL?

Which has preferable valuation and earnings, CYPH or AVXL?

Is CYPH or AVXL more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYPH vs. The Competition

Cypherpunk Technologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools